Literature DB >> 22843427

Pharmacological management of co-morbid conditions at the end of life: is less more?

S McLean1, B Sheehy-Skeffington, N O'Leary, A O'Gorman.   

Abstract

BACKGROUND: Co-morbid conditions (CMCs) are present in over half of patients with cancer over 50 years of age. As life-limiting illnesses progress, the benefits and burdens of treatments for CMCs become unclear. Relevant issues include physiological changes in advanced illness, time-to-benefit of medications, burden of medications, and psychological impact of discontinuing medications. Optimal prescribing is unclear due to lack of evidence.
OBJECTIVES: The objectives are to determine prescribing practice, for CMCs, in a single SPC service.
METHODS: Patients referred to a single specialist palliative care (SPC) service, who died between 1/8/2010 and 30/9/2012, were identified. Medical notes were reviewed, and data collected on prescribing at 3 months, 1 month, and 1 week prior to death.
RESULTS: Fifty-two patients with a median age of 74.5 years were identified; 41 patients (79%) had a malignant condition. 50% died in hospital. Patients had a mean of three CMCs. A mean of 4.6 medications for CMCs were prescribed to patients over 65. A mean of 10 medications in total were prescribed at 1 week before death. One week before death, one-third of patients continued to be prescribed aspirin, and over one-quarter a statin.
CONCLUSIONS: Total medication burden increases as time to death shortens, due to continuation of medications for CMCs, and addition of medications for symptom control. There is a need for research to demonstrate the impact of polypharmacy at the end of life, in order to formulate a framework to guide practice.

Entities:  

Mesh:

Year:  2012        PMID: 22843427     DOI: 10.1007/s11845-012-0841-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  17 in total

Review 1.  Managing comorbidities in patients at the end of life.

Authors:  James Stevenson; Amy P Abernethy; Cathy Miller; David C Currow
Journal:  BMJ       Date:  2004-10-16

2.  Reconsidering medication appropriateness for patients late in life.

Authors:  Holly M Holmes; Déon Cox Hayley; G Caleb Alexander; Greg A Sachs
Journal:  Arch Intern Med       Date:  2006-03-27

Review 3.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

4.  Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use.

Authors:  Maria J Silveira; Anamaria Segnini Kazanis; Matthew P Shevrin
Journal:  J Palliat Med       Date:  2008-06       Impact factor: 2.947

5.  Caregivers experiences of managing medications for palliative care patients at the end of life: a qualitative study.

Authors:  Barbara Sheehy-Skeffington; Sarah McLean; Michael Bramwell; Norma O'Leary; Aisling O'Gorman
Journal:  Am J Hosp Palliat Care       Date:  2014-03       Impact factor: 2.500

6.  Withdrawal of statins increases event rates in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Steven Snapinn; Michael Böhm; Harvey D White
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

7.  Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy.

Authors:  Doron Garfinkel; Derelie Mangin
Journal:  Arch Intern Med       Date:  2010-10-11

Review 8.  Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis.

Authors:  Pierre Amarenco; Julien Labreuche; Philippa Lavallée; Pierre-Jean Touboul
Journal:  Stroke       Date:  2004-10-28       Impact factor: 7.914

9.  Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.

Authors:  B F Uretsky; J B Young; F E Shahidi; L G Yellen; M C Harrison; M K Jolly
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

10.  There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.

Authors:  Mary P McGowan
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

View more
  11 in total

1.  Associations Between Polypharmacy, Symptom Burden, and Quality of Life in Patients with Advanced, Life-Limiting Illness.

Authors:  Yael Schenker; Seo Young Park; Kwonho Jeong; Jennifer Pruskowski; Dio Kavalieratos; Judith Resick; Amy Abernethy; Jean S Kutner
Journal:  J Gen Intern Med       Date:  2019-02-04       Impact factor: 5.128

Review 2.  Prescribing practices, patterns, and potential harms in patients receiving palliative care: A systematic scoping review.

Authors:  Cathal A Cadogan; Melanie Murphy; Miriam Boland; Kathleen Bennett; Sarah McLean; Carmel Hughes
Journal:  Explor Res Clin Soc Pharm       Date:  2021-07-23

Review 3.  Decision making about change of medication for comorbid disease at the end of life: an integrative review.

Authors:  Ronald T C M van Nordennen; Jan C M Lavrijsen; Kris C P Vissers; Raymond T C M Koopmans
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

4.  Discontinuation of medications at the end of life: A population study in Belgium, based on linked administrative databases.

Authors:  Kristel Paque; Robrecht De Schreye; Monique Elseviers; Robert Vander Stichele; Koen Pardon; Tinne Dilles; Thierry Christiaens; Luc Deliens; Joachim Cohen
Journal:  Br J Clin Pharmacol       Date:  2019-02-22       Impact factor: 4.335

5.  Medication use during end-of-life care in a palliative care centre.

Authors:  Anniek D Masman; Monique van Dijk; Dick Tibboel; Frans P M Baar; Ron A A Mathôt
Journal:  Int J Clin Pharm       Date:  2015-04-09

Review 6.  Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis.

Authors:  Shakti Shrestha; Arjun Poudel; Magnolia Cardona; Kathryn J Steadman; Lisa M Nissen
Journal:  Ther Adv Drug Saf       Date:  2021-10-22

7.  Use of antithrombotics at the end of life: an in-depth chart review study.

Authors:  Bregje A A Huisman; Eric C T Geijteman; Jimmy J Arevalo; Marianne K Dees; Lia van Zuylen; Karolina M Szadek; Agnes van der Heide; Monique A H Steegers
Journal:  BMC Palliat Care       Date:  2021-07-16       Impact factor: 3.234

8.  Polypharmacy in the terminal stage of cancer.

Authors:  Katharina A Kierner; Dietmar Weixler; Eva K Masel; Verena Gartner; Herbert H Watzke
Journal:  Support Care Cancer       Date:  2015-11-05       Impact factor: 3.359

9.  Oxidative stress level is not associated with survival in terminally ill cancer patients: a preliminary study.

Authors:  Chang Hwan Yeom; Youn Seon Choi; Hong Yup Ahn; Su Hey Lee; In Cheol Hwang
Journal:  BMC Palliat Care       Date:  2014-03-21       Impact factor: 3.234

10.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.